Alumis presents envudeucitinib data showing complete skin clearance in 54% of patients at 48 weeks
ALMS•ALMS•ALMS•ALMS•Continuous envudeucitinib treatment resulted in complete skin clearance for 54% of patients at week 48, while 75% achieved at least 90% improvement. Alumis plans to submit an application for plaque psoriasis in the fourth quarter of 2026.
Continuous envudeucitinib treatment achieved complete skin clearance in 54% of patients at week 48, and 75% achieved at least 90% improvement.
Through 48 weeks, serious adverse events occurred in 3.2% of patients, and adverse events led to discontinuation in 3%. Alumis plans to submit a new drug application for plaque psoriasis in the fourth quarter of 2026; a decision is anticipated in the fourth quarter of 2027.
Alumis plans a 2027 Phase 2 biomarker trial of A-005, a CNS-penetrant TYK2 inhibitor.
